[A study from Tel Aviv University found that a South African variant of the CCP (Chinese Communist Party) virus affects people vaccinated with the Pfizer shot more than unvaccinated people.
The study, which has not yet been peer-reviewed, indicated that the B.1.351 variant of the virus—also known as the novel coronavirus—was found eight times more than individuals who were unvaccinated, or 5.4 percent against 0.7 percent. Clalit Health Services, a top Israeli health-care provider, also helped in the study.
“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group,” said Adi Stern of Tel Aviv University. “This means that the South African variant is able, to some extent, to break through the vaccine’s protection.”
The study looked at 400 people who received at least one shot of the Pfizer/BioNTech vaccine and had contracted the COVID-19 variant and compared them to the same number of people who were infected and unvaccinated. Moderna’s vaccine is also used in Israel, but it was not included in the study.
“It is the first in the world to be based on real-world data, showing that the vaccine is less effective against the South Africa variant, compared to both the original virus and the British variant,” said Professor Ran Balicer, director of research at Clalit, according to news reports.]
Excerpt:
[A study from Tel Aviv University found that a South African variant of the CCP (Chinese Communist Party) virus affects people vaccinated with the Pfizer shot more than unvaccinated people.
The study, which has not yet been peer-reviewed, indicated that the B.1.351 variant of the virus—also known as the novel coronavirus—was found eight times more than individuals who were unvaccinated, or 5.4 percent against 0.7 percent. Clalit Health Services, a top Israeli health-care provider, also helped in the study.
“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group,” said Adi Stern of Tel Aviv University. “This means that the South African variant is able, to some extent, to break through the vaccine’s protection.”
The study looked at 400 people who received at least one shot of the Pfizer/BioNTech vaccine and had contracted the COVID-19 variant and compared them to the same number of people who were infected and unvaccinated. Moderna’s vaccine is also used in Israel, but it was not included in the study.
“It is the first in the world to be based on real-world data, showing that the vaccine is less effective against the South Africa variant, compared to both the original virus and the British variant,” said Professor Ran Balicer, director of research at Clalit, according to news reports.]